Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Releases Quarterly Earnings Results, Misses Estimates By $3.23 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Wednesday. The company reported ($3.42) EPS for the quarter, missing the consensus estimate of ($0.19) by ($3.23), FiscalAI reports. The firm had revenue of $1.09 million for the quarter, compared to analyst estimates of $0.74 million.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN ARMP traded up $0.40 during midday trading on Wednesday, hitting $8.61. The company’s stock had a trading volume of 35,713 shares, compared to its average volume of 48,862. Armata Pharmaceuticals has a 1-year low of $0.90 and a 1-year high of $16.34. The firm’s fifty day moving average price is $8.59 and its 200-day moving average price is $6.37. The firm has a market cap of $313.49 million, a P/E ratio of -5.31 and a beta of 1.30.

Analysts Set New Price Targets

Several analysts have issued reports on ARMP shares. HC Wainwright upped their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. JonesTrading began coverage on Armata Pharmaceuticals in a research report on Monday, January 5th. They issued a “buy” rating and a $15.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock worth $690,000 after acquiring an additional 5,342 shares during the last quarter. State Street Corp grew its holdings in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $108,000. Millennium Management LLC acquired a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $164,000. Finally, Renaissance Technologies LLC raised its position in shares of Armata Pharmaceuticals by 65.9% during the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares during the period. Institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.